Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2013

View Archived Issues

Ventria Bioscience and USC receive grant for fusion protein

Researchers develop potential treatment for Batten disease

Daiichi Sankyo to form new company to pursue treatment for DMD

Otsuka Pharmaceutical offers overview of third quarter of fiscal 2012

Phase II trial of tenecteplase in patients with minor stroke begins

ARN-509 demonstrates activity in different prostate cancer populations

Oramed Pharmaceuticals gives update on IND for oral insulin

Auris Medical completes enrollment in phase II AM-101 study

Vanderbilt University and GSK to develop novel treatments for severe obesity

Bristol-Myers Squibb presents results of the phase III READY trial in mCRPC

Verastem seeks orphan drug status for VS-6063 in mesothelioma

German researchers present new matrix metalloproteinase inhibitors

Novo Nordisk discloses novel monoclonal antibodies

Teva Pharmaceutical Industries synthesizes novel IL-17RA mutants

First-in-human results presented for AMG-208 in patients with advanced solid tumors

Lycus synthesizes novel melatonin receptor ligands

New tyrosine-protein kinase inhibitors patented by Boehringer Ingelheim

Novartis discloses new agents for macular degeneration

In vitro investigation of the signaling pathways of a novel antimitotic estradiol analogue

VENICE trial shows no improvement in overall survival for aflibercept

New disintegrating tablet formulation of Diovan approved in Japan

Hexvix indication expanded in Europe

FDA accepts resubmission of oral treprostinil NDA

BioAlliance Pharma to extend phase II trial of Validive to the U.S.

Novo Nordisk launches NovoSeven pre-filled syringe for bleeding control in Europe and U.S.

St George's and Orphan Technologies sign agreement to develop new therapies for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...